Pralatrexate: basic understanding and clinical development

Bibliography

• Sirotnak FM, DeGraw JI, Schmid FA, New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 1984;12:26-30
   PubMed Web of Science ®Google Scholar
• Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-28
   PubMed Web of Science ®Google Scholar
• Whetstine JR, Witt TL, Matherly LH. The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. J Biol Chem 2002;277:43873-80
   PubMed Web of Science ®Google Scholar
• Moscow JA, Gong M, He R, Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790-4
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93
   PubMed Web of Science ®Google Scholar
• Bertino JR. The mechanism of action of the folate antagonists in man. Cancer Res 1963;23:1286-306
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999;19:91-122
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Moccio DM, New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 1984;12:18-25
   PubMed Web of Science ®Google Scholar
• DeGraw JI, Colwell WT, Piper JR, Sirotnak FM. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 1993;36:2228-31
   PubMed Web of Science ®Google Scholar
• Wang ES, O'Connor O, She Y, Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027-35
   PubMed Web of Science ®Google Scholar
• Izbicka E, Diaz A, Streeper R, Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009;64:993-9
   PubMed Web of Science ®Google Scholar
• Schmid FA, Sirotnak FM, Otter GM, DeGraw JI. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985;69:551-3
   PubMedGoogle Scholar
• Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998;42:313-18
   PubMed Web of Science ®Google Scholar
• Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 2008;11:508-21
   PubMed Web of Science ®Google Scholar
• O'Connor OA. Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006;18:591-7
   PubMed Web of Science ®Google Scholar
• Krug LM, Ng KK, Kris MG, Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 2000;6:3493-8
   PubMed Web of Science ®Google Scholar
• Krug LM, Azzoli CG, Kris MG, 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003;9:2072-8
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Krug LM, Gomez J, A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 2007;13:2692-8
   PubMed Web of Science ®Google Scholar
• Krug LM, Heelan RT, Kris MG, Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol 2007;2:317-20
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Hamlin P, Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009;27:4357-64
   PubMed Web of Science ®Google Scholar
• O'Connor O, Pinter-Brown L, Popplewell L. PROPEL: results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) [abstract 8561]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Harris NL, Jaffe ES, Diebold J, The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November, 1997. Hematol J 2000;1:53-66
   PubMedGoogle Scholar
• Cheson BD, Horning SJ, Coiffier B, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53
   PubMed Web of Science ®Google Scholar
• Pro B, Coiffier B, Horwitz SM, Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL study: implications for vitamin prophylaxis. ASH Annual Meeting Abstracts 2009;114:1681
   Google Scholar
• Horwitz SM, Duvic M, Kim Y, Pralatrexate is active in cutaneous T-Cell lymphoma (CTCL): results of a multicenter, dose-finding trial. ASH Annual Meeting Abstracts 2009;114:919
   Google Scholar
• Stevens SR, Ke MS, Parry EJ, Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002;138:42-8
   PubMed Web of Science ®Google Scholar
• Hoovis ML, Chu MY. Enhancement of the antiproliferative action of 1-H-D-arabinofuranosylcytosine by methotrexate in murine leukemic cells (L5178Y). Cancer Res 1973;33:521-5
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803-9
   PubMed Web of Science ®Google Scholar
• Toner LE, Vrhovac R, Smith EA, The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:924-32
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Vose JM, Advani R, Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: phase 1 results. ASH Annual Meeting Abstracts 2009;114:1674
   Google Scholar
• Marchi E, Paoluzzi L, Venkatraman SE, O'Connor OA. Pralatrexate (PDX) compliments the activity of the proteasome inhibitor bortezomib (B) in in vitro models of lymphoid T-cell malignancies. ASH Annual Meeting Abstracts 2008;112:3619
   Google Scholar
• Mould DR, Sweeney K, Duffull SB, A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2009;86:190-6
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Krug L, Miller V, Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid supplementation in patients (pts) with advanced non-small-cell lung cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:13006
   Google Scholar
• Fury MG, Krug LM, Azzoli CG, A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol 2006;57:671-7
   PubMed Web of Science ®Google Scholar